NanoCarrier Co., Ltd. (JP:4571)

:4571

4571

NanoCarrier Co., Ltd.

RESEARCH TOOLSreports

Want to see JP:4571 full AI Analyst Report?

NanoCarrier Co., Ltd. (4571) Price & Analysis

2 Followers

4571 Stock Chart & Stats

¥134.00

-¥1.00(-0.68%)

At close: Jan 08 4:00 PM EST

¥134.00

-¥1.00(-0.68%)

Day’s Range― - ―

52-Week Range¥124.00 - ¥254.00

Previous CloseN/A

Volume236.30K

Average Volume (3M)2.35M

Market Cap

¥10.78B

Enterprise Value¥8.65B

Total Cash (Recent Filing)¥3.40B

Total Debt (Recent Filing)¥540.24M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.86

Shares Outstanding75,374,160

10 Day Avg. Volume484,410

30 Day Avg. Volume2,345,523

Financial Highlights & Ratios

PEG Ratio-1.80

Price to Book (P/B)3.71

Price to Sales (P/S)93.58

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary DDS PlatformNanoCarrier’s micellar nanoparticle DDS is a durable, hard-to-replicate technology that supports licensing and partnership revenue models. As a platform asset, it creates structural value through milestones, royalties and partner-led development, keeping long-term upside tied to external approvals and commercialization.

High Gross MarginsSustained gross margins near 72% indicate the company’s core technology and revenue streams are asset-light and scalable. Once fixed R&D and G&A are controlled or supported by partners, margin structure supports profitability potential and attractive economics for licensing-led revenue over time.

Manageable LeverageLow leverage and materially reduced debt provide financial flexibility to fund near-term operations and negotiate partnerships without excessive default risk. This balance-sheet positioning lowers immediate liquidity pressure and preserves capacity to raise incremental capital if development milestones require funding.

Bears Say

Shrinking Revenue TrendA multi-year decline in revenue undermines scale, reduces operating leverage, and weakens the firm’s ability to convert R&D into recurring licensing or royalty income. Persistent top-line contraction also makes it harder to fund fixed costs and erodes partner confidence in the company’s commercial momentum.

Persistent Negative Operating Cash FlowConsistent operating cash burn means the company cannot self-fund development activities and will remain reliant on financing, partner payments or asset sales. This structural cash shortfall increases dilution risk, compresses runway, and constrains strategic flexibility to advance programs independently.

Large Losses Eroding EquityDeep, ongoing operating and net losses are eroding the capital base and produce very negative ROE. Structural unprofitability reduces shareholder value over time, limits reinvestment capacity, and heightens dependency on external funding, increasing long-term execution and financing risk.

NanoCarrier Co., Ltd. News

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an announcement. Nano Holdings, Inc., a Japan-based healthcare value creation...

2M ago

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

7M ago

4571 FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was ¥124.00 and its highest was ¥254.00 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is ¥10.78B.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is May 20, 2026 which is in 26 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on Feb 13, 2026. The company reported -¥2.86 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.86.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 75,374,160 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -¥2.86 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.797%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4571

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.